European heart journal

European heart journal
Audio Summaries

Every issue of European heart journal moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.

188 audio summariesNLM Catalog

Specialties

European heart journal covers research in these specialties.

Recent summaries

The latest articles summarized from European heart journal.

Acute pulmonary embolism: long-term cause-specific mortality in a Chinese nationwide registry.

Nov 20, 2026

This nationwide Chinese registry study of 66,192 hospitalised acute pulmonary embolism patients asked how and why patients die over the long term. At 60 months, cumulative all-cause mortality was 22.4%, with cardiovascular causes (11.8%) and non-cardiovascular causes (10.6%) contributing nearly equally, and the leading causes shifted over time from acute PE and ischaemic heart disease early on to malignancy at 1-3 months and ischaemic heart disease thereafter. Exploratory analyses linked older age, residence in Western China, and abnormal vital signs to higher mortality, supporting the need for risk-adapted long-term follow-up strategies.

Climate change: the patient perspective.

Nov 19, 2026

This CardioPulse article, based on an online interview with members of the ESC Patient Forum, examines how climate change, particularly heat waves, affects the treatment of cardiac patients. The author explores how the cardiology community could better inform and prepare these patients for climate-related risks. The piece centers on the patient perspective rather than presenting new quantitative research.

Sex-specific mortality in ischaemic heart disease across Western Europe: 2023 Global Burden of Disease.

Nov 18, 2026

This study uses Global Burden of Disease 2023 data to ask whether women and men with ischaemic heart disease (IHD) face comparable risk of dying once the disease is present, rather than just looking at overall mortality rates. The authors calculated a prevalence-adjusted "mortality-to-prevalence ratio" and risk-factor-specific case-fatality indices across Western European countries from 2013 to 2023. They found that while IHD mortality fell more in women than men, women still had a higher case fatality in several countries (e.g., Austria, France, Italy, Spain), with metabolic risk, low physical activity, and low fibre intake driving much of that excess, suggesting sex-disaggregated monitoring can reveal disparities hidden by declining mortality trends.

Artificial intelligence-enhanced electrocardiography for detection and prediction of dilated cardiomyopathy.

Nov 14, 2026

An AI model trained on over 330,000 paired ECG-echocardiogram records was developed to detect dilated cardiomyopathy (DCM) and predict its future onset, asking whether a low-cost ECG could identify disease before it manifests. The model achieved AUROCs of 0.87-0.97 for prevalent DCM, outperformed traditional ECG parameters, and matched echocardiography for predicting incident disease across external cohorts. In genetically at-risk familial cohorts, it showed high 5-year negative predictive values (91.5-95.5%), suggesting it could help exclude short- to mid-term disease and reduce surveillance burden, though positive predictive values were modest (39-42%).

Alcohol and cardiovascular disease: inter-organ crosstalk, microvascular dysfunction, and cardiovascular ageing.

Nov 14, 2026

This review reappraises alcohol's cardiovascular risk, asking whether observational cardioprotection from light-to-moderate drinking holds up against newer genetic, biomarker, and cohort evidence. The authors conclude that alcohol is best seen as a dose-, pattern-, and host-dependent cardiovascular stressor, with distinct phenotypes ranging from arrhythmias and cardiomyopathy to stroke and vascular disease. They propose a systems-cardiology framework linking myocardial, electrical, autonomic, microvascular, and inter-organ mechanisms, with "alcohol-related cardiovascular ageing" as a unifying cumulative process, though direct human evidence for that concept remains incomplete.

Acute aortic syndrome rule-out criteria: development and external validation.

Nov 10, 2026

The authors asked whether a simple bedside rule could safely rule out acute aortic syndrome (AAS) in low-risk patients without further testing, something existing tools like ADD-RS and AORTA fail to do. They derived a seven-variable Acute Aortic Syndrome Rule-Out Criteria (ARC) from the IRAD registry and externally validated it in three prospective cohorts. ARC achieved 100% sensitivity in both external cohorts while ruling out roughly 24–36% of patients (specificity 23.7% and 36.4%), suggesting potential to reduce unnecessary testing pending prospective confirmation of clinical utility.

Sacubitril/valsartan for radiation-induced heart disease in children: preclinical and clinical findings.

Nov 10, 2026

Researchers asked whether early prophylaxis with sacubitril/valsartan can prevent radiation-induced heart disease in children, a population with scarce prospective data. Using a translational pipeline, they found that radiotherapy impaired cardiac function in pediatric cancer patients, that sacubitril/valsartan reduced fibrosis, diastolic dysfunction, and inflammation in a juvenile rat model, and that it improved left ventricular strain and aortic compliance in a small clinical cohort with a favorable safety profile over 12 months. Because the clinical cohort was small (15 per arm), these findings are preliminary and would need confirmation in larger randomized trials.

Promoting integrity in collaborations between academia and the medical industry.

Nov 10, 2026

This conceptual article asks how collaborations between academia and the medical industry can be governed to preserve transparency, independence, and public trust, given inconsistent disclosure rules across institutions and jurisdictions. The authors draw on European and international policies, regulatory experience, and established practice models to define six guiding principles (transparency, independence, accountability, equity, sustainability, and patient-centred benefit). They conclude with practical recommendations, including harmonized public disclosure standards, separation of industry funding from scientific decision-making, stronger institutional accountability, and independent education to support integrity.

Inflammation and early atherosclerosis beyond traditional risk factors: an imaging study.

Nov 10, 2026

This study asked how much systemic inflammation contributes to subclinical atherosclerosis plaque burden beyond LDL cholesterol and systolic blood pressure in middle-aged, asymptomatic adults from the PESA cohort. Using serial blood tests and 3D vascular ultrasound and coronary calcium imaging, the authors found that higher white blood cell count and fibrinogen were independently associated with greater 6-year global plaque volume, with WBC showing an effect (about 33% per SD) comparable in scale to LDL cholesterol and blood pressure. These findings suggest that inflammation is a relevant risk factor across the atherosclerosis continuum, not only in established disease.

Incremental yield of genetic retesting in hypertrophic cardiomyopathy.

Nov 10, 2026

This multicentre study asked whether retesting HCM patients with a prior negative genetic test, using an updated NGS panel that includes newly described genes and deep intronic MYBPC3 regions, would yield new HCM-related variants, and which clinical features predict a positive retest. Of 508 patients, 9% had HCM-related variants, and late gadolinium enhancement plus high Mayo and Toronto HCM scores identified patients most likely to benefit (diagnostic yield of 80% with LGE and a high Toronto score). These findings suggest that LGE and risk scores can be used to prioritize which previously tested patients should be retested.

Listen to European heart journal

14-day free trial. Every new article, summarized in ~3 minutes.